UroGen Pharma (URGN) Cost of Revenue (2018 - 2026)

UroGen Pharma's Cost of Revenue history runs 8 years deep, the most recent figure standing at $4.1 million for Q1 2026.

• Quarterly Cost of Revenue rose 77.64% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.3 million (up 50.33% YoY) and the FY2025 annual result came in at $12.4 million, up 40.15% from the prior year.
• Cost of Revenue was $4.1 million for Q1 2026 at UroGen Pharma, up from $3.3 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $4.1 million in Q1 2026 and bottomed at $1.5 million in Q1 2022.
• A 5-year average of $2.5 million and a median of $2.3 million in 2025 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2024 — Cost of Revenue slipped 23.71% — and 2026, when it surged 77.64%.
• UroGen Pharma's Cost of Revenue stood at $2.3 million in 2022, then climbed by 1.02% to $2.3 million in 2023, then grew by 8.09% to $2.5 million in 2024, then soared by 33.1% to $3.3 million in 2025, then grew by 25.84% to $4.1 million in 2026.
• Business Quant data shows URGN's Cost of Revenue at $4.1 million in Q1 2026, $3.3 million in Q4 2025, and $3.3 million in Q3 2025.